Literature DB >> 6403102

Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes.

J M Lord, S I White, C J Bailey, T W Atkins, R F Fletcher, K G Taylor.   

Abstract

To investigate the effect of metformin on insulin receptor binding and diabetic control, eight obese type II diabetic patients were studied before treatment, after one and four weeks of taking metformin (500 mg thrice daily), and four weeks after withdrawal of the drug. After one and four weeks of treatment the number of erythrocyte insulin receptors had increased by 116% and 184% respectively. This was due almost entirely to an increase in the number of low affinity binding sites. The number of receptors was still raised four weeks after metformin had been withdrawn. Diabetic control as assessed by urinary glucose, glycosylated haemoglobin (HbA1), and glucose tolerance values was significantly improved during metformin treatment, while plasma insulin concentrations were not altered. These results indicate that metformin produces a rapid and protracted increase in low affinity insulin receptors in type II diabetes, associated with greater insulin sensitivity and improved diabetic control.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403102      PMCID: PMC1547150          DOI: 10.1136/bmj.286.6368.830

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  12 in total

Review 1.  Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness.

Authors:  H E Lebovitz; M N Feinglos
Journal:  Diabetes Care       Date:  1978 May-Jun       Impact factor: 19.112

2.  Determination of glucose by an automatic analyser.

Authors:  J F Stevens
Journal:  Clin Chim Acta       Date:  1971-04       Impact factor: 3.786

3.  Determination of metformin in biological samples.

Authors:  M S Lennard; C Casey; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

4.  Biguanide treatment increases the number of insulin-receptor sites on human erythrocytes.

Authors:  A Holle; W Mangels; M Dreyer; J Kühnau; H W Rüdiger
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

5.  Erythrocyte and monocyte insulin binding in man: a comparative analysis in normal and disease states.

Authors:  R F Dons; J Ryan; P Gorden; H Wachslicht-Rodbard
Journal:  Diabetes       Date:  1981-11       Impact factor: 9.461

6.  Effects of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetic patients.

Authors:  J M Olefsky; G M Reaven
Journal:  Am J Med       Date:  1976-01       Impact factor: 4.965

7.  Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide.

Authors:  H Beck-Nielsen; O Pedersen; H O Lindskov
Journal:  Acta Endocrinol (Copenh)       Date:  1979-03

8.  Characteristics of human erythrocyte insulin receptors.

Authors:  K K Gambhir; J A Archer; C J Bradley
Journal:  Diabetes       Date:  1978-07       Impact factor: 9.461

9.  Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus.

Authors:  O G Kolterman; R S Gray; J Griffin; P Burstein; J Insel; J A Scarlett; J M Olefsky
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

Review 10.  Metformin: a review of its pharmacological properties and therapeutic use.

Authors:  L S Hermann
Journal:  Diabete Metab       Date:  1979-09
View more
  10 in total

Review 1.  [Value of biguanide in therapy of diabetes mellitus].

Authors:  E Haupt; U Panten
Journal:  Med Klin (Munich)       Date:  1997-08-15

2.  Metformin enhances certain insulin actions in cultured rat hepatoma cells.

Authors:  F Purrello; D Gullo; M Buscema; V Pezzino; R Vigneri; I D Goldfine
Journal:  Diabetologia       Date:  1988-06       Impact factor: 10.122

3.  Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations.

Authors:  F Gregorio; F Ambrosi; P Marchetti; S Cristallini; R Navalesi; P Brunetti; P Filipponi
Journal:  Acta Diabetol Lat       Date:  1990 Apr-Jun

Review 4.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

5.  Characterization of Huh7 cells after the induction of insulin resistance and post-treatment with metformin.

Authors:  José Manuel Villalva-Pérez; Marco Antonio Ramírez-Vargas; Jesús Isimar Serafín-Fabían; Mónica Ramírez; Ma Elena Moreno-Godínez; Mónica Espinoza-Rojo; Eugenia Flores-Alfaro
Journal:  Cytotechnology       Date:  2020-05-14       Impact factor: 2.058

6.  Captopril-induced acute renal artery thrombosis and persistent anuria in a patient with documented pre-existing renal artery stenosis and renal failure.

Authors:  P S Williams; M S Hendy; P Ackrill
Journal:  Postgrad Med J       Date:  1984-08       Impact factor: 2.401

7.  Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Effect of metformin on hepatocyte insulin receptor binding in normal, streptozotocin diabetic and genetically obese diabetic (ob/ob) mice.

Authors:  J M Lord; T W Atkins; C J Bailey
Journal:  Diabetologia       Date:  1983-08       Impact factor: 10.122

Review 9.  Treatment of non-insulin-dependent diabetes mellitus and its complications. A state of the art review.

Authors:  A Ilarde; M Tuck
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

Review 10.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.